Romero, AlejandroRamos, EvaLopez-Muñoz, FranciscoGil-Martin, EmilioEscames, GermaineReiter, Russel J2023-02-092023-02-092020-08-05Romero A, Ramos E, López-Muñoz F, Gil-Martín E, Escames G, Reiter RJ. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? Cell Mol Neurobiol. 2022 Apr;42(3):489-500.http://hdl.handle.net/10668/16074The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.enCOVID-19Central nervous systemMelatoninNeuroinvasionNeuroprotectionSARS-CoV-2AnimalsBrainCOVID-19Central Nervous SystemCentral Nervous System AgentsCentral Nervous System Viral DiseasesHumansMelatoninNeuroprotective AgentsSARS-CoV-2COVID-19 Drug Treatmentresearch article32772307Restricted AccessAnimalesEncéfaloEnfermedades virales del sistema nervioso centralFármacos neuroprotectoresFármacos del sistema nervioso centralHumanosMelatoninaSARS-CoV-2Sistema nervioso centralTratamiento farmacológico de COVID-1910.1007/s10571-020-00938-81573-6830PMC7415199https://link.springer.com/content/pdf/10.1007/s10571-020-00938-8.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415199/pdf